A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading ...

Food manufacturers are trying to whip themselves up a forkful of the slimming trend — but nutrition experts aren’t giving them a good review.

Dosing a statin (rosuvastatin ... and the Hartford Hospital Cholesterol Management Center. Approximately 2600 charts were reviewed to identify patients receiving rosuvastatin EOD who previously ...

Share on Pinterest New research links Ozempic to a rare side effect that may affect eye health. Design by MNT; Photography by Community Eye Health, CC BY-NC 2.0 & NurPhoto/Getty Images Two large ...

Allowing yourself grace, patience and respect." Though Aguilera's appearance has sparked debate online about whether she has dabbled with Ozempic, the "Beautiful" singer has not directly addressed ...

Known by trade names such as Ozempic, Wegovy, and others, these GLP-1 agonists have dramatically reduced obesity for diabetes patients, and their use has quickly broadened into popular culture.

The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays.

GLP-1 agonists like Ozempic effectively help manage obesity, but quitting the medication can lead to a resurgence in weight and related health issues. Gradual cessation is advised to avoid sudden ...

Ozempic and its peers ... report that the appetite-suppressing effects weaken over time, necessitating dosage adjustments to sustain efficacy." People on GLP-1 drugs who have more than $125,000 ...